

GLP-1-based Medications Dosing Guide for Type 2 Diabetes

Generic (Brand)	Initiation Dose	Frequency Route Titration	Dose Escalation	Renal Dosing eGFR (mL/min)	Pen Type Needle Rx	FDA Labeled Indication:		Clinical Considerations
						ASCVD (MACE reduction)	CKD	
Dulaglutide (Trulicity)	0.75 mg	Weekly Injection Q4 weeks ^b	1.5 mg	FOR ALL AGENTS IN PATIENTS WITH RENAL DISFUNCTION: NO DOSE ADJUSTMENT NECESSARY	Single Use Auto-injector	☒		ASCVD Risk Reduction Population: with established CV or with multiple CV risk factors
			3 mg					
			4.5 mg					
Liraglutide (Victoza)	0.6 mg ^a	Once Daily Injection Q1 week ^b	1.2 mg		Multi Dose Needs Rx	☒		Needle Rx: 31G x 5mm recommended Authorized generic available
			1.8 mg					
Semaglutide (Ozempic)	0.25 mg ^a	Weekly Injection Q4 weeks ^b	0.5 mg		Multi Dose No Rx	☒	☒	Pen needles: 4-6 included
			1 mg					
			2 mg					
Semaglutide (Ozempic Pill)	1.5 mg ^a	Once Daily Oral Tablet Q30 days ^b	4 mg			☒		Must be taken on an empty stomach with up to 4 oz of water, 30 mins before eating or drinking. Not waiting 30 min or taking with liquids other than water, impacts absorption and efficiency
			9 mg					
Tirzepatide (Mounjaro)	2.5 mg ^a	Weekly Injection Q4 weeks ^b	5 mg		Single Use Auto-injector			Due to drug interaction with oral contraceptives , recommend adding a barrier method for 4 weeks after initiation AND for 4 weeks after every dose escalation. Alternatively, discuss other highly effective contraceptive options.
			7.5 mg					
			10 mg					
			12.5 mg					
			15 mg					

a: Sensitizing dose has no little to no glycemic benefit.

b: Consider longer interval for titration if known or current moderate to severe GI side effects.

ASCVD Risk Reduction Population:

- Dula: with established CV or with multiple CV risk factors
- Lira: with established CV
- Sema SQ: with established CV
- Sema PO: at high risk for MACE events



Switching Guide for
GLP-1-based Medications
michmed.org/W3wR2

DEFINITIONS

ASCVD: Atherosclerotic cardiovascular disease

CKD: Chronic kidney disease

CV: Cardiovascular

eGFR: Estimated glomerular filtration rate

MACE: Major adverse cardiovascular events

uACR: Urine albumin-to-creatinine ratio

SGLT2 Inhibitors Dosing Guide for Type 2 Diabetes

Generic (Brand)	Dose Initiation	Frequency of Oral Tablet	Dose Escalation ^a	Renal Dosing eGFR (mL/min)	FDA Labeled Indication:			Clinical Considerations
					ASCVD	CKD	Heart Failure	
Canagliflozin (Invokana)	100 mg	Once Daily	300 mg (if eGFR ≥ 60)	eGFR 30 to <59: 100 mg daily MAX EXCEPTION! If eGFR < 30 AND Severe Albuminuria (>300 mg/g): Continue 100 mg (See clinical considerations)	☒	☒		CKD labeled indication: Specific to patients with eGFR <30 AND with severe albuminuria. ASCVD labeled indication: Specific to reduction of MACE
Dapagliflozin (Farxiga)	5 mg	Once Daily	10 mg	eGFR < 45: Do NOT use for glycemic lowering EXCEPTION! Continue to use for non-T2D indications (when eGFR < 45): See table below.		☒	☒	
Empagliflozin (Jardiance)	10 mg	Once Daily	25 mg	eGFR < 30: Do NOT use for T2D EXCEPTION! Continue to use for non-T2D indications (when eGFR < 30): See table below.	☒	☒	☒	ASCVD labeled indication: Specific to reduction of CV death
Ertugliflozin (Steglatro)	5 mg	Once Daily	15 mg	eGFR < 45: Do NOT use for glycemic lowering				
Bexagliflozin (Brenzavvy)	20 mg	Once Daily	N/A	eGFR < 30: Do NOT use for glycemic lowering				Price: ~ \$50 per month Available at ONLINE pharmacies only (See brenzavvy.com)

a: **Timing of dose escalation (4-12 weeks):** In addition to glycemic needs, consider tolerance (BP, renal function) and adverse effects (urinary frequency, genital mycotic infections, volume status) prior to escalation.

b: **SGLT2is in dialysis:** Early studies and post-hoc analyses suggest that SGLT2i can be safely used in selected dialysis patients, especially those with residual kidney function.

For Patients with CKD without Type 2 Diabetes: SGLT2i Renal Dosing

Dapagliflozin (Farxiga)		
	eGFR < 25	eGFR 25 - 45
CKD	Ok to continue 10 mg daily (do NOT initiate)	10 mg daily (starting dose)
Heart Failure		
On Dialysis: Individualize^b		

Empagliflozin (Jardiance)	
	eGFR 20 - 30
CKD	10 mg daily
Heart Failure	
On Dialysis: Individualize^b	